The 5 testing & diagnostics services stocks we track reported a very strong Q3. As a group, revenues beat analysts’ consensus ...

The blood-based test by Astrin Biosciences shows high sensitivity and specificity across cancer stages and subtypes, ...

Risk-based screening, including genetic testing, is noninferior to annual screening for detecting stage ≥IIB cancers and does ...

University of California, San Francisco investigators led WISDOM, a randomized comparison of risk-based breast cancer ...

A new generation of AI algorithms aim to go beyond detecting cancers to predicting risk for cardiovascular diseases.

A study of more than 45,000 women found that screening women according to their level of risk was as effective in detecting ...

A new study published in JAMA suggests that risk-based breast cancer screening could be a more effective approach than annual mammograms, but some experts fear it would be hard to do in practice.

New findings suggest blood tests still being assessed are showing promising results for early cancer screenings, especially ...

Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional ...

The blood test also had a sensitivity and specificity of 92.3% and 92.6% for participants who do not have breast cancer. The results were consistent for women with dense breast tissue and non-dense ...

Breast cancer comes with many variables. A pair of powerful genomic tests can help women and their care teams make ...